Authors' objectives: Post‒COVID-19 condition, also referred to as long COVID or post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), among other names, is a condition characterized by new or persisting symptoms beyond the acute phase of the disease (e.g., for more than 4 or 12 weeks following an initial COVID-19 infection, clinical definition pending). People with post‒COVID-19 may experience a range of heterogenous symptoms including fatigue, shortness of breath, muscle aches, and cognitive and mental health challenges. Although the clinical pathophysiology of the condition is not yet well-defined, it is increasingly being recognized that is affects multiple organs and may have severe impacts to a person’s well-being and quality of life. CADTH, in consultation with its customers, is undertaking a Condition Level Review on post‒COVID-19. A Condition Level Review is an assessment of the evidence on a range of health technologies and emerging issues on all aspects of the condition, including prevention, identification, treatment, and management.

Project Status: Ongoing

URL for protocol: https://www.cadth.ca/sites/default/files/pdf/htis/2021/RE0040%20Post%20COVID-19%20Scoping%20Review%20draft%20protocol-Final.pdf

Anticipated Publish Date: 2022

URL for additional information: https://cadth.ca/post-covid-19-condition-condition-level-review

English language abstract: An English language summary is available

Publication Type: Rapid Review

Country: Canada

Organisation Name: Canadian Agency for Drugs and Technologies in Health

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright:

Canadian Agency for Drugs and Technologies in Health (CADTH)